
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics is pursuing precision medicine with a well diversified and competitively priced pipeline in various stages of development. Along with strong partnerships, regulatory clarity and financial stability, the company puts a strong emphasis on the patient's quality of life and drug tolerability. With consistent symptom score improvement and potential for lower dosing, it has the potential to differentiate itself from other drugs in the space, making it a good investment choice for the future.
Bears say
Relay Therapeutics is currently overvalued and its stock is at risk of significant decline. The company's technology may have potential in precision medicine, but it is still early stage and risky. With only one drug candidate in phase 1 trials, it may take a considerable amount of time and resources for Relay Therapeutics to bring a product to market and generate revenue. Additionally, the company's high reliance on its proprietary Dynamo platform and recent equity offering raise concerns about its financial stability and long-term prospects.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares